$CVAT
Cavitation Technologies, Inc. Stock $cvat

$cvat Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000168316823006921 Filed on October 03, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$0.00	$52.00K	$413.0K
YoY Change	-100.0%	-94.6%	-74.49%
Cost Of Revenue	$0.00	$48.00K	$121.0K
YoY Change	-100.0%	-4900.0%	195.12%
Gross Profit	$0.00	$4.000K	$312.0K
YoY Change	-100.0%	-99.59%	-80.79%
Gross Profit Margin		7.69%	75.54%
Selling, General & Admin	$214.0K	$323.0K	$1.192M
YoY Change	-19.25%	-46.7%	-31.02%
% of Gross Profit		8075.0%	382.05%
Research & Development	$36.00K	$3.000K	$3.000K
YoY Change		200.0%	-82.35%
% of Gross Profit		75.0%	0.96%
Depreciation & Amortization		$2.000K	$3.000K
YoY Change
% of Gross Profit		50.0%	0.96%
Operating Expenses	$250.0K	$326.0K	$1.198M
YoY Change	-5.66%	-46.29%	-37.7%
Operating Profit	-$250.0K	-$322.0K	-$886.0K
YoY Change	362.96%	-190.2%	196.32%
Interest Expense	$1.000K	-$1.108M	$6.000K
YoY Change	0.0%	1203.53%	20.0%
% of Operating Profit
Other Income/Expense, Net		$0.00	-$1.154M
YoY Change			260.63%
Pretax Income	-$251.0K	-$1.430M	-$2.040M
YoY Change	243.84%	-1621.28%	229.56%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$251.0K	-$1.430M	-$2.040M
YoY Change	243.84%	-1621.28%	229.56%
Net Earnings / Revenue		-2750.0%	-493.95%
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	284.3M shares	282.2M shares	281.7M shares
Diluted Shares Outstanding	284.3M shares		281.7M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$140.0K	$18.00K
YoY Change	-61.85%	-95.92%
Cash & Equivalents	$140.0K	$18.00K
Short-Term Investments
Other Short-Term Assets		$0.00
YoY Change		-100.0%
Inventory		$0.00
Prepaid Expenses		$0.00
Receivables		$0.00
Other Receivables		$0.00
Total Short-Term Assets	$140.0K	$18.00K
YoY Change	-67.67%	-96.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$1.000K
YoY Change	-75.0%	-75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.000K	$1.000K
YoY Change	-99.91%	-99.91%
Other Assets	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$107.0K	$125.0K
YoY Change	-91.82%	-90.69%
TOTAL ASSETS
Total Short-Term Assets	$140.0K	$18.00K
Total Long-Term Assets	$107.0K	$125.0K
Total Assets	$247.0K	$143.0K
YoY Change	-85.81%	-92.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$144.0K	$120.0K
YoY Change	3.6%	-11.11%
Accrued Expenses	$394.0K	$348.0K
YoY Change	14.87%	1.46%
Deferred Revenue	$695.0K	$391.0K
YoY Change	1830.56%	388.75%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000K	$5.000K
YoY Change
Total Short-Term Liabilities	$1.238M	$864.0K
YoY Change	139.0%	54.84%
LONG-TERM LIABILITIES
Long-Term Debt	$145.0K	$145.0K
YoY Change	-3.33%	-3.33%
Other Long-Term Liabilities	$34.00K	$53.00K
YoY Change	-69.09%	-58.27%
Total Long-Term Liabilities	$179.0K	$145.0K
YoY Change	19.33%	-47.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.238M	$864.0K
Total Long-Term Liabilities	$179.0K	$145.0K
Total Liabilities	$1.417M	$1.062M
YoY Change	82.13%	27.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.54M	-$27.29M
YoY Change	8.76%	8.08%
Common Stock	$284.0K	$284.0K
YoY Change	2.53%	2.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.170M	-$919.0K
YoY Change
Total Liabilities & Shareholders Equity	$247.0K	$143.0K
YoY Change	-85.81%	-92.36%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$251.0K	-$1.430M	-$2.040M
YoY Change	243.84%	-1621.28%	229.56%
Depreciation, Depletion And Amortization		$2.000K	$3.000K
YoY Change
Cash From Operating Activities	$122.0K	-$292.0K	-$423.0K
YoY Change	-264.86%	-13.61%	-12.6%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	$0.00
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	$122.0K	-292.0K	-$423.0K
Cash From Investing Activities		0.000	$0.00
Cash From Financing Activities	0.000	0.000	$0.00
Net Change In Cash	$122.0K	-292.0K	-$423.0K
YoY Change	-264.86%	-13.61%	-54.12%
FREE CASH FLOW
Cash From Operating Activities	$122.0K	-$292.0K	-$423.0K
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$292.0K	-$423.0K
YoY Change		-13.61%	-12.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001376793
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	CVAT	Cashless Exercise Of Warrants CashlessExerciseOfWarrants		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	CVAT	Cashless Exercise Of Warrants CashlessExerciseOfWarrants		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Entity File Number EntityFileNumber	000-53239
CY2023	dei	Entity Registrant Name EntityRegistrantName	Cavitation Technologies, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4907818
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	10019 CANOGA AVENUE
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	CHATSWORTH
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91311
CY2023	dei	City Area Code CityAreaCode	(818)
CY2023	dei	Local Phone Number LocalPhoneNumber	718-0905
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	5395000	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	284289740	shares
CY2023	dei	Auditor Name AuditorName	Weinberg & Company, P.A.
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	441000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	48000	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	18000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	528000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1149000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	113000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	180000	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	10000	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	10000	usd
CY2023Q2	us-gaap	Assets Assets	143000	usd
CY2022Q2	us-gaap	Assets Assets	1871000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	120000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	135000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	280000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	280000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	5000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	391000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	80000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	864000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	558000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	145000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	127000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1062000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	835000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	284289740	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	284289740	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	276698831	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	276698831	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	284000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	277000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26083000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26005000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27286000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25246000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-919000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1036000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1871000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	413000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1619000	usd
CY2023	CVAT	Revenue Related Party RevenueRelatedParty	20000	usd
CY2022	CVAT	Revenue Related Party RevenueRelatedParty	46000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	121000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	41000	usd
CY2023	us-gaap	Gross Profit GrossProfit	312000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1624000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1195000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1728000	usd
CY2023	CVAT	Impairment Of Equipment ImpairmentOfEquipment	0	usd
CY2022	CVAT	Impairment Of Equipment ImpairmentOfEquipment	178000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1198000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1923000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-886000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-299000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	104000	usd
CY2023	CVAT	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	0	usd
CY2022	CVAT	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	-371000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1148000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-48000	usd
CY2023	us-gaap	Interest Expense InterestExpense	6000	usd
CY2022	us-gaap	Interest Expense InterestExpense	5000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1154000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-320000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2040000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-619000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2040000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-619000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	281693701	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	281693701	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	248736262	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	248736262	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-411000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	785000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	40000	usd
CY2022	CVAT	Fair Value Of Common Stock Issued Upon Exercise Of Warrants And Options FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptions	87000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	225000	usd
CY2022	CVAT	Fair Value Of Common Stock Issued To Settle Liabilities FairValueOfCommonStockIssuedToSettleLiabilities	929000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-619000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1036000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	85000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2040000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-919000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2040000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-619000	usd
CY2023	us-gaap	Depreciation Depreciation	3000	usd
CY2022	us-gaap	Depreciation Depreciation	0	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	87000	usd
CY2023	CVAT	Fair Value Of Warrants Granted For Services FairValueOfWarrantsGrantedForServices	0	usd
CY2022	CVAT	Fair Value Of Warrants Granted For Services FairValueOfWarrantsGrantedForServices	40000	usd
CY2023	CVAT	Fair Value Of Common Stock Issued For Services FairValueOfCommonStockIssuedForServices	85000	usd
CY2022	CVAT	Fair Value Of Common Stock Issued For Services FairValueOfCommonStockIssuedForServices	225000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	104000	usd
CY2023	CVAT	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	-0	usd
CY2022	CVAT	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	-371000	usd
CY2023	CVAT	Impairment Of Equipment ImpairmentOfEquipment	0	usd
CY2022	CVAT	Impairment Of Equipment ImpairmentOfEquipment	178000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	48000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1148000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-48000	usd
CY2023	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	0	usd
CY2022	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	26000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	23000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-38000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	38000	usd
CY2023	CVAT	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	67000	usd
CY2022	CVAT	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	65000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-15000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-33000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	311000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-647000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-69000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-61000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-423000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-484000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1223000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1223000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	785000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	785000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-423000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-922000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1363000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	CVAT	Liabilities Settled With Common Stock LiabilitiesSettledWithCommonStock	0	usd
CY2022	CVAT	Liabilities Settled With Common Stock LiabilitiesSettledWithCommonStock	558000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2040000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-423000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-919000	usd
CY2023Q2	us-gaap	Cash Cash	18000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zZwV8CKWylB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86E_zYwgcpMDGOo5">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	48000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	0	usd
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	1112000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	44000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	106000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zLewkVewrtqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zRDeVkgbsu0b">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2023, we recorded <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_z4LMmIIkM0C5" title="Concentration risk percentage">95</span>% of our revenue from Desmet Ballestra (Desmet) and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_z0dQkEVe1vHe" title="Concentration risk percentage">5</span>% from Enviro Watertek, LLC (EW) (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, we recorded <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zibI78Klh15b" title="Concentration risk percentage">97</span>% of our revenue from Desmet and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zl1VGh9Rzsna" title="Concentration risk percentage">3</span>% from EW (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2023 and 2022, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zqoI8KVwrE8a" title="Concentration risk percentage">0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zRFoVZ75amtb" title="Concentration risk percentage">100</span>%, respectively, of accounts receivable were due from EW.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	76000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	78000	usd
CY2023	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	72000	usd
CY2022	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	72000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.04	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.04	pure
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	113000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	180000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	127000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	121000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	190000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	78000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	53000	usd
CY2023Q2	CVAT	Lessee Operating Lease Liability Payment Due LesseeOperatingLeaseLiabilityPaymentDue	131000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	121000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	524000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	524000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	523000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	520000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2023	us-gaap	Depreciation Depreciation	3000	usd
CY2022	us-gaap	Depreciation Depreciation	0	usd
CY2023	us-gaap	Equipment Expense EquipmentExpense	178000	usd
CY2021Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	667000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	280000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	280000	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	150000	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	150000	usd
CY2022	CVAT	Stock Issued For Warrant And Option Exercises Shares StockIssuedForWarrantAndOptionExercisesShares	778609	shares
CY2022	CVAT	Stock Issued For Warrant And Option Exercises Value StockIssuedForWarrantAndOptionExercisesValue	87000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.28	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.28	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	12500000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3505000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3063000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	962000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	938000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4467000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4001000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4467000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4001000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd

Files In Submission

Name	View Source	Status
cvat-20230630_def.xml	Edgar Link	unprocessable
cvat-20230630_cal.xml	Edgar Link	unprocessable
0001683168-23-006921-index-headers.html	Edgar Link	pending
0001683168-23-006921-index.html	Edgar Link	pending
0001683168-23-006921.txt	Edgar Link	pending
0001683168-23-006921-xbrl.zip	Edgar Link	pending
cavitation_ex3101.htm	Edgar Link	pending
cavitation_ex3102.htm	Edgar Link	pending
cavitation_ex3201.htm	Edgar Link	pending
cavitation_ex3202.htm	Edgar Link	pending
cavitation_i10k-063023.htm	Edgar Link	pending
cvat-20230630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
cvat-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvat-20230630_pre.xml	Edgar Link	unprocessable
cavitation_i10k-063023_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVAT
Cavitation Technologies, Inc. Stock $cvat

2023 Q3 Form 10-K Financial Statement

#000168316823006921 Filed on October 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVAT Cavitation Technologies, Inc. Stock $cvat

2023 Q3 Form 10-K Financial Statement

#000168316823006921 Filed on October 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVAT
Cavitation Technologies, Inc. Stock $cvat